cautionary tale
The mole problem: what dermatologists actually fear about Melanotan II
Of everything laid at Melanotan II’s feet, the concern dermatologists return to is the simplest, and the hardest to wave away: it changes your moles. Not metaphorically. Visibly, and sometimes dramatically.
What’s documented
Melanotan II drives melanocytes throughout the body, not only in the places you’d like a tan. The dermatology literature carries repeated reports of the predictable consequence. In one case published in 2012, a man in his twenties erupted more than a hundred new melanocytic nevi within weeks of a short course of MT-II; the most atypical of them, biopsied, came back as dysplastic with severe atypia. Other reports describe existing moles darkening and enlarging and new ones appearing over a span of months.
This is not fringe or disputed. A compound that tells pigment cells to switch on will switch on the pigment cells in your moles too.
The melanoma question, held honestly
Two things are true at once here, and this site holds both rather than picking the scarier or the more reassuring one.
First: melanoma has been diagnosed in Melanotan users, and those cases are in the peer-reviewed literature — the British Journal of Dermatology and the journal Dermatology among others have reported them, including a woman in her twenties found to have a melanoma some months after a brief course of MT-II.
Second: these are case reports. A case report can raise an alarm; it cannot prove the drug caused the cancer. Melanocortin signaling does influence melanocyte behavior, which makes a causal link biologically plausible — but “plausible” and “proven” are different words, and the honest state of the evidence is that causation is unresolved. Unresolved is not the same as harmless. It means the question is open, and open questions about melanoma are not comfortable ones.
The subtler harm needs no causation at all
Here is the part that bites even if Melanotan II never causes a single melanoma. Early melanoma is caught by change — the mole that darkens, grows, or shifts shape. “Evolving” is the E in the ABCDE rule every dermatologist and every screening campaign relies on. Change is the signal.
A drug whose defining action is darkening and changing moles raises the noise floor under that signal. The melanoma that would have announced itself by changing is now one changing mole among dozens. Whatever Melanotan II does or doesn’t do to cancer risk directly, it degrades the exact early-warning system that makes melanoma survivable when caught early. For a compound descended from a melanoma-prevention project, that is a bitter thing to be true.
Who has the most to lose
The harm concentrates in the people least able to absorb it. One reported case involved a teenager with familial atypical multiple mole–melanoma syndrome — a germline predisposition to the disease — who developed eruptive dysplastic nevi after pairing Melanotan with a tanning bed. For someone whose moles are already the thing their dermatologist watches most closely, blurring that picture isn’t a cosmetic side effect. It’s sabotage of the one defense they have.
Pigment shows up in less obvious places too. Melanonychia — dark longitudinal bands in the nails — is a documented Melanotan effect, and is itself something clinicians otherwise screen as a possible sign of cancer.
The tan fades. The surveillance problem is what lingers — in the charts of the people whose whole job is to catch the thing early, on skin that a drug has made harder to read. It’s the most important entry in the whole side-effect ledger, and the one least visible to the person in the mirror.